Data from Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma

Tumor-infiltrating lymphocytes
DOI: 10.1158/2767-9764.c.6713699 Publication Date: 2023-06-26T14:30:14Z
ABSTRACT
<div><p>The successful use of expanded tumor-infiltrating lymphocytes (TIL) in adoptive TIL therapies has been reported, but the effects expansion, immunophenotype, function, and T cell receptor (TCR) repertoire infused products relative to tumor microenvironment (TME) are not well understood. In this study, we analyzed samples (<i>n</i> = 58) from treatment-naïve patients with renal carcinoma (RCC), “pre-rapidly expanded” TILs (pre-REP TIL, <i>n</i> 15) “rapidly (REP 25) according a clinical-grade production protocol, single-cell RNA (scRNA)+TCRαβ-seq (TCRαβ sequencing), TCRβ-sequencing (TCRβ-seq), flow cytometry. REP encompassed greater abundance CD4<sup>+</sup> than CD8<sup>+</sup> cells, increased LAG-3 low PD-1 expressions both compartments compared pre-REP cells. The protocol preferentially small clones phenotype (<i>CD4</i>, <i>IL7R</i>, <i>KLRB1</i>) TME, indicating that largest exhausted do expand during expansion protocol. addition, by generating catalog RCC-associated TCR motifs >1,000 scRNA+TCRαβ-seq TCRβ-seq RCC, healthy other cancer sample cohorts, quantified TCRs Unlike low-remaining amount anti-viral throughout quantity was high tumors decreased TILs. Our results provide an in-depth understanding origin, phenotype, specificity RCC products, paving way for more rationalized TILs.</p>Significance:<p>TILs heterogenous group immune cells recognize attack tumor, thus utilized various clinical trials. our explored kidney expanding using as observed their characteristics ability experimental computational tools.</p></div>
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (0)